Jemma Arakelyan: Discussing dMMR colorectal cancers at Asian Congress
Jemma Arakelyan, Medical Oncologist and the Chief Executive Officer of The Institute of Cancer and Crisis, posted the following on X:
“Had an amazing time at ASBIC2024 in Guilin! Shoutout to my fellow scientists—who knew they could sing so well? Let’s connect and bridge the gap between academia and clinical practice!”
Dr. Jemma Arakelyan is a medical oncologist and the Chief Executive Officer of The Institute of Cancer and Crisis. Under her leadership, the Institute is dedicated to raising awareness and providing support for cancer patients facing critical challenges, including those arising from war and pandemics. Currently, she is pursuing her Ph.D. at the City University of Hong Kong, focusing on the development of new anticancer treatments and the mechanisms driving cancer progression. In addition to her academic work, Dr. Arakelyan is actively involved in several scientific organizations, including the European School of Oncology (ESO), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). She also serves as an advisor at the Immune Oncology Research Institute, where they work closely on the clinical development of novel immunotherapeutic agents.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023